Paper Details

  1. Home
  2. Paper Details

Darunavir/cobicistat once daily for the treatment of HIV.

Author: CrauwelsHerta, IterbekeKoen, KakudaThomas N, OpsomerMagda, TomakaFrank, VanveggelSimon, de SmedtGoedele, van de CasteeleTom

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Cobicistat, a newer agent for boosting plasma drug levels of darunavir, is a more specific cytochrome P450 3A inhibitor than ritonavir without enzyme-inducing properties. This review discusses the differing effects of cobicistat and ritonavir on metabolic enzymes, their drug-drug interactions, and the clinical development and data for a once-daily darunavir/cobicistat fixed-dose combination (FDC).
Paper Details　
Original Abstract of the Article :
A current focus in HIV management is improving adherence by minimizing pill burden with convenient formulations, including fixed-dose combinations (FDCs). Darunavir, a HIV protease inhibitor, co-administered with low-dose ritonavir (800/100 mg once daily), is recommended in guidelines in combination...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1586/14787210.2015.1033400

データ提供：米国国立医学図書館（NLM）

Once-Daily Darunavir/Cobicistat for HIV Treatment: A Step Towards Improved Adherence

HIV treatment has significantly evolved over the years, and improving patient adherence to medication is a constant priority. This study explores the potential of a [once-daily fixed-dose combination (FDC) of darunavir and cobicistat] as a convenient and effective treatment for HIV patients. The combination of [darunavir and ritonavir] is currently a standard treatment, but the once-daily FDC with cobicistat offers a more user-friendly and efficient approach.

The Power of Convenience: Simplifying HIV Treatment with Darunavir/Cobicistat

Cobicistat, a more specific cytochrome P450 3A inhibitor than ritonavir, effectively boosts darunavir plasma levels without enzyme-inducing properties. The once-daily FDC of darunavir/cobicistat allows for a simpler treatment regimen, reducing the pill burden and potentially improving adherence. This convenient approach could significantly impact patients' lives by simplifying their treatment and potentially leading to better outcomes.

Navigating HIV Treatment: Choosing the Right Path

The development of this once-daily FDC represents a significant advancement in HIV treatment. By reducing pill burden and simplifying treatment regimens, this innovative approach has the potential to improve adherence and enhance patient outcomes. As a wise camel, I always emphasize the importance of seeking guidance from qualified healthcare professionals to ensure you receive the most appropriate treatment for your specific needs. With the right combination of treatment and support, individuals living with HIV can manage their condition effectively and live fulfilling lives.

Dr. Camel's Conclusion

This study highlights the ongoing advancements in HIV treatment, focusing on optimizing patient adherence. By simplifying medication regimens with a once-daily FDC, this approach offers a promising path toward improved treatment outcomes. The future of HIV treatment is bright, with continued research and innovation leading the way.

Date :
  1. Date Completed 2016-02-11
  2. Date Revised 2015-05-12
Further Info :

Pubmed ID

25962100

DOI: Digital Object Identifier

10.1586/14787210.2015.1033400

Related Literature

Article Analysis
・Effects of darunavir and cobicistat
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.